R848, which normally activates both TLR7 and TLR8 on DCs, macrophages and neutrophils, activates the CD56brightCD16− NK cell subpopulation only via TLR8, highlighting the potential role of TLR8-targeted infiltrating TME-NK cells as a novel tumor immunotherapy [56]. This evidence concerns the gene TLR7 and neoplasm.